Liver disease biotech Vital Therapies revives IPO filing, removes original terms


Shutterstock photo

Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to raise $75 million by selling 4.4 million shares at $16 to $18 per share but postponed on November 21, 2013. The company's updated filing removed the original IPO terms.

The San Diego, CA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. Credit Suisse and William Blair are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by